● Recruiting
Phase III
Oncology
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
What is being tested: Sonesitatug vedotin (an antibody-drug conjugate targeting Claudin18.2) combined with capecitabine, with or without rilvegostomig (an ADAM10 inhibitor), as first-line treatment…
09 Sep 2026
NCT07431281